Asiaticoside Mitigates Alzheimer's Disease Pathology by Attenuating Inflammation and Enhancing Synaptic Function

被引:8
|
作者
Liu, Sai [1 ,2 ]
Chen, Long [1 ,2 ]
Li, Jinran [1 ,2 ]
Sun, Yuan [1 ,2 ]
Xu, Yue [3 ]
Li, Zhaoxing [4 ,5 ]
Zhu, Zheying [6 ]
Li, Xinuo [1 ,2 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Jiangsu Prov Key Lab Drug Metab & Pharmacokinet, Nanjing 210009, Peoples R China
[3] Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmacol, Columbus, OH 43210 USA
[4] China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China
[5] China Pharmaceut Univ, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Peoples R China
[6] Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England
关键词
Alzheimer's disease; Asiaticoside; synapse; inflammation; p38; MAPK; MAPK; NEUROINFLAMMATION; REGULATOR; PROTEINS; THERAPY; KINASE;
D O I
10.3390/ijms241511976
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease (AD) is a prevalent neurodegenerative disorder, hallmarked by the accumulation of amyloid-& beta; (A & beta;) plaques and neurofibrillary tangles. Due to the uncertainty of the pathogenesis of AD, strategies aimed at suppressing neuroinflammation and fostering synaptic repair are eagerly sought. Asiaticoside (AS), a natural triterpenoid derivative derived from Centella asiatica, is known for its anti-inflammatory, antioxidant, and wound-healing properties; however, its neuroprotective function in AD remains unclear. Our current study reveals that AS, when administered (40 mg/kg) in vivo, can mitigate cognitive dysfunction and attenuate neuroinflammation by inhibiting the activation of microglia and proinflammatory factors in A & beta;(1-42)-induced AD mice. Further mechanistic investigation suggests that AS may ameliorate cognitive impairment by inhibiting the activation of the p38 MAPK pathway and promoting synaptic repair. Our findings propose that AS could be a promising candidate for AD treatment, offering neuroinflammation inhibition and enhancement of synaptic function.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Synaptic pathology in Alzheimer's disease
    Davisson, P
    Blennow, K
    NEUROCHEMISTRY: CELLULAR, MOLECULAR, AND CLINICAL ASPECTS, 1997, : 39 - 46
  • [2] Synaptic pathology in Alzheimer's disease
    Davidsson, P
    Blennow, K
    JOURNAL OF NEUROCHEMISTRY, 1996, 66 : S3 - S3
  • [3] Synaptic pathology in Alzheimer's disease
    Marie, H.
    JOURNAL OF NEUROCHEMISTRY, 2017, 142 : 35 - 35
  • [4] Synaptic Mitochondrial Pathology in Alzheimer's Disease
    Du, Heng
    Guo, Lan
    Yan, Shirley ShiDu
    ANTIOXIDANTS & REDOX SIGNALING, 2012, 16 (12) : 1467 - 1475
  • [5] Mechanisms of synaptic pathology in Alzheimer's disease
    Masliah, E
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1998, (53): : 147 - 158
  • [6] Targeting synaptic pathology in Alzheimer's disease
    Cao, Jing
    Zhang, Yun-Wu
    ZOOLOGICAL RESEARCH, 2024, 45 (04) : 875 - 876
  • [7] Sumoylation impact on synaptic function and alzheimer disease pathology
    Fraser, P.
    Takamura, H.
    Matsuzaki, S.
    Katayama, T.
    Arancio, O.
    JOURNAL OF NEUROCHEMISTRY, 2019, 150 : 49 - 49
  • [8] SUMOylation affects synaptic function and Alzheimer disease pathology
    Takamura, H.
    Matsuzaki, S.
    Katayama, T.
    Arancio, O.
    Fraser, P.
    JOURNAL OF NEUROCHEMISTRY, 2019, 150 : 221 - 221
  • [9] Neurogranin in Alzheimer's Disease: Roles in synaptic function, pathology, and potential as a diagnostic biomarker
    Bavaharini, Rajkumar
    Somala, Chaitanya Sree
    Saravanan, Konda Mani
    Anand, Thirunavukarasou
    AIMS MOLECULAR SCIENCE, 2024, 11 (04): : 330 - 350
  • [10] Cholesterol, synaptic function and Alzheimer's disease
    Koudinov, AR
    Koudinova, NV
    PHARMACOPSYCHIATRY, 2003, 36 : S107 - S112